WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4.

WHIM(warts, hypogammaglobulinemia, recurrent bacterial infection, and myelokathexis) syndrome is a rare immunodeficiency caused in many cases by autosomal dominant C-terminal truncation mutations in the chemokine receptor CXCR4. A prominent and unexplained feature of WHIM is myelokathexis (hypercellularity with apoptosis of mature myeloid cells in bone marrow and neutropenia). We transduced healthy human CD34(+) peripheral blood-mobilized stem cells (PBSCs) with retrovirus vector encoding wild-type (wt) CXCR4 or WHIM-type mutated CXCR4 and studied these cells ex vivo in culture and after engraftment in a nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse xenograft model. Neither wt CXCR4 nor mutated CXCR4 transgene expression itself enhanced apoptosis of neutrophils arising in transduced PBSC cultures even with stimulation by a CXCR4 agonist, stromal cell-derived factor-1 (SDF-1 [CXCL12]). Excess wt CXCR4 expression by transduced human PBSCs enhanced marrow engraftment, but did not affect bone marrow (BM) apoptosis or the release of transduced leukocytes into PB. However, mutated CXCR4 transgene expression further enhanced BM engraftment, but was associated with a significant increase in apoptosis of transduced cells in BM and reduced release of transduced leukocytes into PB. We conclude that increased apoptosis of mature myeloid cells in WHIM is secondary to a failure of marrow release and progression to normal myeloid cell senescence, and not a direct effect of activation of mutated CXCR4.

[1]  M. de la Luz Sierra,et al.  G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. , 2006, Blood.

[2]  J. Bagley,et al.  Inhibition of CD26 peptidase activity significantly improves engraftment of retrovirally transduced hematopoietic progenitors , 2006, Gene Therapy.

[3]  J. Dipersio,et al.  Role of CXCR4 Chemokine Receptor Blockade Using AMD3100 for Mobilization of Autologous Hematopoietic Progenitor Cells , 2005, Acta Haematologica.

[4]  J. Dipersio,et al.  The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. , 2005, Blood.

[5]  J. Dick,et al.  Human short-term repopulating stem cells are efficiently detected following intrafemoral transplantation into NOD/SCID recipients depleted of CD122+ cells. , 2005, Blood.

[6]  U. Choi,et al.  Enhanced function with decreased internalization of carboxy-terminus truncated CXCR4 responsible for WHIM syndrome. , 2005, Experimental hematology.

[7]  George Diaz CXCR4 mutations in WHIM syndrome: a misguided immune system? , 2005, Immunological reviews.

[8]  U. Choi,et al.  CXCR4‐Transgene Expression Significantly Improves Marrow Engraftment of Cultured Hematopoietic Stem Cells , 2004, Stem cells.

[9]  U. Choi,et al.  Progress toward effective gene therapy for chronic granulomatous disease. , 2004, Japanese journal of infectious diseases.

[10]  H. Broxmeyer,et al.  Modulation of Hematopoietic Stem Cell Homing and Engraftment by CD26 , 2004, Science.

[11]  A. Pegg,et al.  Nuclear-localizing O6-benzylguanine-resistant GFP-MGMT fusion protein as a novel in vivo selection marker. , 2004, Experimental hematology.

[12]  K. Malcolm,et al.  Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil homeostasis. , 2004, Blood.

[13]  L. Notarangelo,et al.  Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. , 2004, Blood.

[14]  S. Karlsson,et al.  Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. , 2004, Blood.

[15]  A. V. Gulino WHIM syndrome: a genetic disorder of leukocyte trafficking , 2003, Current opinion in allergy and clinical immunology.

[16]  D. Bodine,et al.  Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/beta -microglobulin-/- repopulating mobilized human peripheral blood CD34+ cells. , 2003, Blood.

[17]  B. Wood,et al.  Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. , 2003, Blood.

[18]  S. Rankin,et al.  Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. , 2003, Immunity.

[19]  R. Gorlin,et al.  Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease , 2003, Nature Genetics.

[20]  V. Robert-Hebmann,et al.  Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling. , 2003, Blood.

[21]  H. Broxmeyer,et al.  Cell Surface Peptidase CD26/Dipeptidylpeptidase IV Regulates CXCL12/Stromal Cell-Derived Factor-1α-Mediated Chemotaxis of Human Cord Blood CD34+ Progenitor Cells1 , 2002, The Journal of Immunology.

[22]  D. Link,et al.  G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. , 2002, Immunity.

[23]  J. Rasko,et al.  Sustained multilineage gene persistence and expression in dogs transplanted with CD34(+) marrow cells transduced by RD114-pseudotype oncoretrovirus vectors. , 2001, Blood.

[24]  S. Taniuchi,et al.  Dizygotic twin sisters with myelokathexis: Mechanism of its neutropenia , 1999, American journal of hematology.

[25]  C. Tailor,et al.  A Sodium-Dependent Neutral-Amino-Acid Transporter Mediates Infections of Feline and Baboon Endogenous Retroviruses and Simian Type D Retroviruses , 1999, Journal of Virology.

[26]  Kouji Matsushima,et al.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.

[27]  S. Holland,et al.  Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Whitlock,et al.  Clinical Features of Myelokathexis and Treatment with Hematopoietic Cytokines: A Case Report of Two Patients and Review of the Literature , 1997, Journal of pediatric hematology/oncology.

[29]  L. To,et al.  The biology and clinical uses of blood stem cells. , 1997, Blood.

[30]  Y Takeuchi,et al.  High-titer packaging cells producing recombinant retroviruses resistant to human serum , 1995, Journal of virology.

[31]  M. Miyasaka,et al.  Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice , 1993, The Journal of experimental medicine.

[32]  T. Taniguchi,et al.  A novel monoclonal antibody against murine IL-2 receptor beta-chain. Characterization of receptor expression in normal lymphoid cells and EL-4 cells. , 1991, Journal of immunology.

[33]  M. Stratton,et al.  Characterization of the human cell line TE671. , 1989, Carcinogenesis.

[34]  T. Barbui,et al.  Myelokathexis: a rare form of chronic benign granulocytopenia , 1984, British journal of haematology.

[35]  R. Graham,et al.  'Myelokathexis': Neutropenia With Narrow Hyperplasia , 1977 .

[36]  R. Graham,et al.  'Myelokathexis'. Neutropenia with marrow hyperplasia. , 1977, American journal of diseases of children.

[37]  W. Zuelzer,et al.  "MYELOKATHEXIS"--A NEW FORM OF CHRONIC GRANULOCYTOPENIA. REPORT OF A CASE. , 1964, The New England journal of medicine.